Comparison of ME/CFS and Long COVID-19 Patients

Sponsor
Solve ME/CFS Initiative (Other)
Overall Status
Recruiting
CT.gov ID
NCT04806620
Collaborator
(none)
10,000
1
60
166.7

Study Details

Study Description

Brief Summary

The purpose of the You + ME Registry and Biobank is to collect clinical and patient-reported data and biological samples (e.g. blood) from people living with Myalgic Encephalomyelitis (also known as chronic fatigue syndrome or ME/CFS), people with long-COVID and control volunteers to improve understanding, diagnosis and treatment of these diseases.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The You + ME Registry and Biobank is a collection of clinical and patient-reported data and biological samples (e.g. blood) from people living with Myalgic Encephalomyelitis (also known as chronic fatigue syndrome or ME/CFS), people with long-COVID and control volunteers. The patient registry collates demographic and real-world, longitudinal symptom, patient-reported outcomes, and treatment data from a global cohort into a centralized repository. The Registry will also be linked to a biobank which is a place that stores tissues, blood or other samples from participants. The combination of data and biological samples will be made available to researchers so we can: (1) improve our understanding of the natural history, epidemiology, pathogenesis, resilience/susceptibility factors, disease subsets, and treatment of ME/CFS and long-COVID using a standardized set of demographic and longitudinal data; (2) build an infrastructure and resource to support a range of future research into these diseases; (3) increase opportunities for collaboration between patients, providers, researchers, and industry.

    Anyone 18 years of age and older is invited to sign up. After creating a profile and completing an informed consent via an online portal, participants fill out a series of surveys, including medical history, co-occurring conditions, symptoms, quality of life, functional status, and treatments. Participants receive email reminders to complete follow-up surveys to provide researchers with information about their health over time.

    The Registry also includes a mobile tracking app co-created with the community that allows participants to monitor at minimum five core symptoms of fatigue, brain fog, unrefreshing sleep, and orthostatic intolerance (on a scale of 0: symptom absent - 4: very severe) as well as any additional symptoms of their choosing, life factors, and activity. Individuals can also capture data in narrative form using a journaling function. Participants are encouraged to capture data every 3 days if possible, but can track as often as daily.

    Registry data is stored in a secure, encrypted database. Data is anonymized before being made available on a secure platform for research. Biosamples collected from participants are labeled with a coded number to protect their privacy and confidentiality.

    This project is supported by Solve ME/CFS Initiative. You can learn more and sign up at youandmeregistry.com.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    10000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Comparison of ME/CFS and Long COVID-19 Patients
    Actual Study Start Date :
    May 1, 2020
    Anticipated Primary Completion Date :
    May 1, 2025
    Anticipated Study Completion Date :
    May 1, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    People with ME/CFS

    No intervention will be administered.

    People with Long-COVID

    No intervention will be administered.

    Healthy Controls

    No intervention will be administered.

    Outcome Measures

    Primary Outcome Measures

    1. Phenotypic data collection [24 months]

      We want to collect a large, well-characterized longitudinal dataset to understand causes and identify treatments for ME/CFS and long-COVID.

    2. Subtyping [24 months]

      We aim to use the phenotypic and associated biological samples from the Registry to identify disease subtypes.

    Secondary Outcome Measures

    1. Demographics [24 months]

      We record basic demographic information of our Registry population including: age, race, ethnicity, income, education, employment, marital status. Demographic information is recorded at baseline and updated every 12 months.

    2. Comorbitities [24 months]

      We want to catalogue common comorbidities in our registry population. Participants provide information on diagnosed conditions, age of onset, and whether the condition is still active. Their conditions list can be updated over time.

    3. Treatments [24 months]

      We want to catalogue commonly used treatments in our registry population. Participants provide information on past and current treatments and provide ratings of their effectiveness at relieving symptoms. Their treatments list can be updated over time and information on ongoing use can be recorded via a mobile app.

    4. Quality of Life and Functional Status [24 months]

      Participants fill out the Short Form 36 Quality of Life survey and a version of the Karnofsky Performance Scale modified for self-report over time.

    5. Symptoms [24 months]

      We want to catalogue the common symptoms of ME/CFS and long COVID and analyze the data for symptom-based phenotypes. We administer a survey to assess the frequency and severity of symptoms over time and provide access to a mobile app so participants can log data on their symptoms as often as daily.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients with ME/CFS,

    • Those without ME/CFS

    • Patients with long-COVID

    • Patients with COVID who recovered.

    Exclusion Criteria:
    • Those who never had COVID

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Solve ME/CFS Initiative Los Angeles California United States 91206

    Sponsors and Collaborators

    • Solve ME/CFS Initiative

    Investigators

    • Study Director: Sadie Whittaker, PhD, Solve ME/CFS Initiative

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Solve ME/CFS Initiative
    ClinicalTrials.gov Identifier:
    NCT04806620
    Other Study ID Numbers:
    • 1
    First Posted:
    Mar 19, 2021
    Last Update Posted:
    Apr 6, 2021
    Last Verified:
    Apr 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 6, 2021